Compare Abeona Therapeutics Inc (ABEO) vs Chewy Inc (CHWY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Chewy Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Chewy Inc trades at $20.69 (market cap $8.49B). The key difference: Chewy Inc is far larger — about 22.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Chewy Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | CHWY | |
|---|---|---|
Market Cap | $373.32M | $8.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $42.33 |
52-Week Low | $4.17 | $17.51 |
Enterprise Value | $228.22M | $8.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Chewy (CHWY) trades at $20.73, down 0.58% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported $11.86B in revenue for 2025 with a net income margin of 1.99%, showing improved profitability from prior years. Recent news highlights market share gains through its Autoship program and expansion into pet healthcare services, though the stock faces pressure from lowered 2026 growth expectations.
The outlook remains positive with an 81.58% buy rating from analysts and a $34.92 consensus price target, suggesting significant upside. Key risks include competitive pressures in the pet care sector and execution challenges in integrating new veterinary services. Investors should weigh strong customer loyalty and recurring revenue streams against near-term volatility and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →
